-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
In -X- _ O
order -X- _ O
to -X- _ O
identify -X- _ O
novel -X- _ O
chemical -X- _ O
classes -X- _ O
of -X- _ O
β-secretase -X- _ B-Patient
( -X- _ I-Patient
BACE-1 -X- _ I-Patient
) -X- _ I-Patient
inhibitors -X- _ O
, -X- _ O
an -X- _ O
alternative -X- _ O
scoring -X- _ O
protocol -X- _ O
, -X- _ O
Principal -X- _ B-Intervention
Component -X- _ I-Intervention
Analysis -X- _ I-Intervention
( -X- _ I-Intervention
PCA -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
was -X- _ O
proposed -X- _ O
to -X- _ O
summarize -X- _ O
most -X- _ O
of -X- _ O
the -X- _ O
information -X- _ O
from -X- _ O
the -X- _ O
original -X- _ O
scoring -X- _ O
functions -X- _ O
and -X- _ O
re-rank -X- _ O
the -X- _ O
results -X- _ O
from -X- _ O
the -X- _ O
virtual -X- _ O
screening -X- _ O
against -X- _ O
BACE-1. -X- _ B-Patient
METHOD -X- _ O
: -X- _ O
Given -X- _ O
a -X- _ O
training -X- _ O
set -X- _ O
( -X- _ O
50 -X- _ O
BACE-1 -X- _ O
inhibitors -X- _ O
and -X- _ O
9950 -X- _ O
inactive -X- _ O
diverse -X- _ O
compounds -X- _ O
) -X- _ O
, -X- _ O
three -X- _ O
rank-based -X- _ O
virtual -X- _ O
screening -X- _ O
methods -X- _ O
, -X- _ O
individual -X- _ B-Comparison
scoring -X- _ I-Comparison
, -X- _ O
conventional -X- _ B-Intervention
consensus -X- _ I-Intervention
scoring -X- _ I-Intervention
and -X- _ I-Intervention
PCA -X- _ I-Intervention
, -X- _ O
were -X- _ O
judged -X- _ O
by -X- _ O
the -X- _ O
hit -X- _ O
number -X- _ O
in -X- _ O
the -X- _ O
top -X- _ O
1 -X- _ O
% -X- _ O
of -X- _ O
the -X- _ O
ranked -X- _ O
list. -X- _ O
The -X- _ O
docking -X- _ O
poses -X- _ O
were -X- _ O
generated -X- _ O
by -X- _ O
Surflex -X- _ O
, -X- _ O
five -X- _ O
scoring -X- _ O
functions -X- _ O
( -X- _ O
Surflex_Score -X- _ O
, -X- _ O
D_Score -X- _ O
, -X- _ O
G_Score -X- _ O
, -X- _ O
ChemScore -X- _ O
, -X- _ O
and -X- _ O
PMF_Score -X- _ O
) -X- _ O
were -X- _ O
used -X- _ O
for -X- _ O
pose -X- _ O
extraction. -X- _ O
For -X- _ O
each -X- _ O
pose -X- _ O
group -X- _ O
, -X- _ O
twelve -X- _ O
scoring -X- _ O
functions -X- _ O
( -X- _ O
Surflex_Score -X- _ O
, -X- _ O
D_Score -X- _ O
, -X- _ O
G_Score -X- _ O
, -X- _ O
ChemScore -X- _ O
, -X- _ O
PMF_Score -X- _ O
, -X- _ O
LigScore1 -X- _ O
, -X- _ O
LigScore2 -X- _ O
, -X- _ O
PLP1 -X- _ O
, -X- _ O
PLP2 -X- _ O
, -X- _ O
jain -X- _ O
, -X- _ O
Ludi_1 -X- _ O
, -X- _ O
and -X- _ O
Ludi_2 -X- _ O
) -X- _ O
were -X- _ O
used -X- _ O
for -X- _ O
the -X- _ O
pose -X- _ O
rank. -X- _ O
For -X- _ O
a -X- _ O
test -X- _ O
set -X- _ O
, -X- _ O
113,228 -X- _ O
chemical -X- _ O
compounds -X- _ O
( -X- _ O
Sigma-Aldrich® -X- _ O
corporate -X- _ O
chemical -X- _ O
directory -X- _ O
) -X- _ O
were -X- _ O
docked -X- _ O
by -X- _ O
Surflex -X- _ O
, -X- _ O
then -X- _ O
ranked -X- _ O
by -X- _ O
the -X- _ O
same -X- _ O
three -X- _ O
ranking -X- _ O
methods -X- _ O
motioned -X- _ O
above -X- _ O
to -X- _ O
select -X- _ O
the -X- _ O
potential -X- _ O
active -X- _ O
compounds -X- _ O
for -X- _ O
experimental -X- _ O
test. -X- _ O
RESULTS -X- _ O
: -X- _ O
For -X- _ O
the -X- _ O
training -X- _ O
set -X- _ O
, -X- _ O
the -X- _ B-Outcome
PCA -X- _ I-Outcome
approach -X- _ I-Outcome
yielded -X- _ I-Outcome
consistently -X- _ I-Outcome
superior -X- _ I-Outcome
rankings -X- _ I-Outcome
compared -X- _ I-Outcome
to -X- _ I-Outcome
conventional -X- _ I-Outcome
consensus -X- _ I-Outcome
scoring -X- _ I-Outcome
and -X- _ I-Outcome
single -X- _ I-Outcome
scoring. -X- _ I-Outcome
For -X- _ I-Outcome
the -X- _ I-Outcome
test -X- _ I-Outcome
set -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
top -X- _ I-Outcome
20 -X- _ I-Outcome
compounds -X- _ I-Outcome
according -X- _ I-Outcome
to -X- _ I-Outcome
conventional -X- _ I-Outcome
consensus -X- _ I-Outcome
scoring -X- _ I-Outcome
were -X- _ I-Outcome
experimentally -X- _ I-Outcome
tested -X- _ I-Outcome
, -X- _ I-Outcome
no -X- _ I-Outcome
inhibitor -X- _ I-Outcome
was -X- _ I-Outcome
found. -X- _ I-Outcome
Then -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
relied -X- _ I-Outcome
on -X- _ I-Outcome
PCA -X- _ I-Outcome
scoring -X- _ I-Outcome
protocol -X- _ I-Outcome
to -X- _ I-Outcome
test -X- _ I-Outcome
another -X- _ I-Outcome
different -X- _ I-Outcome
top -X- _ I-Outcome
20 -X- _ I-Outcome
compounds -X- _ I-Outcome
and -X- _ I-Outcome
two -X- _ I-Outcome
low -X- _ I-Outcome
micromolar -X- _ I-Outcome
inhibitors -X- _ I-Outcome
( -X- _ I-Outcome
S450588 -X- _ I-Outcome
and -X- _ I-Outcome
276065 -X- _ I-Outcome
) -X- _ I-Outcome
were -X- _ I-Outcome
emerged -X- _ I-Outcome
through -X- _ I-Outcome
the -X- _ I-Outcome
BACE-1 -X- _ I-Outcome
fluorescence -X- _ I-Outcome
resonance -X- _ I-Outcome
energy -X- _ I-Outcome
transfer -X- _ I-Outcome
( -X- _ I-Outcome
FRET -X- _ I-Outcome
) -X- _ I-Outcome
assay. -X- _ I-Outcome
CONCLUSION -X- _ O
: -X- _ O
The -X- _ O
PCA -X- _ B-Outcome
method -X- _ I-Outcome
extends -X- _ I-Outcome
the -X- _ I-Outcome
conventional -X- _ I-Outcome
consensus -X- _ I-Outcome
scoring -X- _ I-Outcome
in -X- _ I-Outcome
a -X- _ I-Outcome
quantitative -X- _ I-Outcome
statistical -X- _ I-Outcome
manner -X- _ I-Outcome
and -X- _ I-Outcome
would -X- _ I-Outcome
appear -X- _ I-Outcome
to -X- _ I-Outcome
have -X- _ I-Outcome
considerable -X- _ I-Outcome
potential -X- _ I-Outcome
for -X- _ I-Outcome
chemical -X- _ I-Outcome
screening -X- _ I-Outcome
applications -X- _ I-Outcome
. -X- _ O

